ClinicalTrials.gg
Not yet recruitingNCT07204080TONIX-1500Updated Nov 16, 2026

(TNX-1500) in Kidney Transplant Recipients

A Phase 2 interventional study of TNX-1500 and Kidney Transplant in Kidney Transplant, Kidney Transplant Failure and Rejection and Immunosuppression, sponsored by Ayman Al Jurdi, MD. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Ayman Al Jurdi, MD · Phase 2, Interventional, and Treatment

How we know

Updated Nov 6, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.

02

Conditions studied

  • Kidney Transplant
  • Kidney Transplant Failure and Rejection
  • Immunosuppression
  • Immunosuppression After Kidney Transplantation

Keywords

  • Kidney Transplant
  • New Immunosuppression
03

In context

Lead sponsor

This is the only study on the registry with Ayman Al Jurdi, MD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects ≥18 to 75 years of age.
  2. Kidney transplant candidates with chronic kidney disease (stage IV or V) or end-stage kidney disease evaluated and listed for transplantation at Massachusetts General Hospital.
  3. Recipient of an ABO-compatible, non-human leukocyte antigen (HLA) identical living or deceased donor kidney (de novo)
  4. Ability to understand the study requirements and provide written .
  5. Epstein-Barr virus (EBV) seropositive

Exclusion criteria

Exclusion Criteria:

  1. Recipient seropositive for (HIV-1), or surface antigen (HBsAg) or core antibody (Anti-HBc); subjects who are seropositive for virus (HCV) are excluded without proof of sustained viral response (SVR) after anti-HCV treatment or spontaneous clearance.
  2. Recipient of a kidney from a donor who tests positive for HIV, HBsAg, Anti-HBc, or HCV NAT.
  3. Subjects with a severe systemic infection, current or within the 2 weeks prior to screening.
  4. \< 40% as determined by TTE or clinical evidence of heart failure.
  5. Any of the following ocular history or ocular findings at screening exam:

    1. Active inflammation in either or both eyes (does not include pigment cell in the AC after dilation); must be greater than trace cell or trace flare to exclude.
    2. Findings that would impact the ability to monitor, diagnose, manage, and follow new onset ocular inflammation.*
    3. Receipt of ocular (topically, intravitreally, or periocularly) or has been treated with anti-VEGF intravitreal therapy within three months of Screening Exam
  6. Pregnant or nursing (lactating) women confirmed by human chorionic gonadotropin (hCG) laboratory test.
  7. Women of (women capable of becoming pregnant) unless using a highly effective method of during dosing and for 24 weeks after study treatment. Highly effective contraception methods include:

    1. Female sterilization (surgical, bilateral oophorectomy with or without hysterectomy), or tubal ligation at least 6 weeks before taking study treatment.
    2. Male sterilization (at least 6 months prior to screening); for female subjects on the study, the vasectomized male partners should be the sole partners for that subject.
    3. Use of injected or implanted hormonal methods of contraception or other hormonal contraception that have comparable efficacy (\<1% for example, hormone vaginal ring or placement of a long-acting reversible contraceptives, an intrauterine device, or intrauterine system.
    4. Total abstinence
  8. Use of other products or enrollment in another investigational drug study within 30 days prior to screening or 5 half-lives, whichever is longer.
  9. Subjects with lab abnormalities (>2.5 x the (ULN) of the following liver function chemistries unless due to, as judged by the investigator, a benign underlying condition:

    1. (ALT)
    2. Aspartate aminotransferase (AST)
    3. Alkaline phosphatase (ALP)
    4. Coagulation studies (international normalization ratio (), prothrombin time (PT), and partial thromboplastin time (PTT))
  10. Any other clinically significant medical condition, active infection, laboratory abnormality, or psychosocial condition (e.g. history of substance use disorder) that would, in the judgement of the investigator, impact the subject's ability to participate in the trial.
  11. Presence of pre-existing donor-specific antibodies (DSA) or calculated panel reactive antibodies (cPRA) >20% based upon results within 6 months prior to transplant.
  12. Virtual crossmatch (VXM) positive transplant with an MFI >1000 as assessed by routine methodology (Luminex)
  13. Cytomegalovirus (CMV) high risk combination: donor positive to recipient negative
  14. Multi-organ transplant or tissue recipient.
  15. History of of any organ system, except for localized excised non-melanomatous skin or carcinoma in situ of the cervix
  16. Subjects with any of the following: \<8 mg/dL, white blood cell ≤2,000/mm3, or count ≤75,000/mm3.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Kidney Transplant Recipient

    Drug: TNX-1500 · Procedure: Kidney Transplant

Interventions

  • DrugTNX-1500

    This is an open-label, single-center, single-arm study to assess the safety of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients.

  • ProcedureKidney Transplant

    Kidney Transplant

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events in each subject

    The primary endpoint is the cumulative incidence of all AEs and SAEs in subjects treated with TNX-1500 at Week 76

    Time frame: 76 Weeks

  2. Number of Serious Adverse Events in each subject

    The primary endpoint is the cumulative incidence of all AEs and SAEs in subjects treated with TNX-1500 at Week 76.

    Time frame: 76 Weeks

Secondary outcomes

  1. Incidence of Biopsy Proven Acute Rejection

    Acute rejection, treatment and outcome biopsy pathology grading (Banff Criteria)

    Time frame: 52 Weeks

  2. Incidence of treatment for acute rejection

    Acute rejection, treatment and outcome biopsy pathology grading (Banff Criteria)

    Time frame: 52 Weeks

  3. Incidence of Biopsy Proven Acute Rejection

    Acute rejection, treatment and outcome biopsy pathology grading (Banff Criteria)

    Time frame: 76 Weeks

  4. Incidence of treatment for acute rejection

    Acute rejection, treatment and outcome biopsy pathology grading (Banff Criteria)

    Time frame: 76 Weeks

  5. Incidence of de novo DSA development

    Time frame: 52 weeks

  6. Incidence of serious opportunistic infections

    based upon AE/SAE data and available quantitative and qualitative EBV and CMV surveillance data

    Time frame: 76 Weeks

  7. Incidence of malignancies

    based upon AE/SAE data and available documenting incidence of malignancy of any grade

    Time frame: 76 Weeks

  8. Incidence of AEs of Special Interest

    based upon AESI/SAE data and available documenting incidence of AESI which include thromboembolic events, Infections \>Grade 2, Any Grade 2 or higher injection site reactions, Any Grade 2 or higher cytokine release syndrome, ophthalmic adverse events.

    Time frame: 76 Weeks

  9. GFR measurement

    Assessment of renal function through the estimated glomerular filtration rate at 12 months post-transplant

    Time frame: 52 Weeks

  10. Incidence of death

    Time frame: 52 Weeks

  11. Incidence of graft loss

    Time frame: 52 Weeks

  12. Degree of Proteinuria

    Proteinuria by urine protein-to-creatinine ratio

    Time frame: 76 Weeks

  13. Degree of albuminuria

    Albuminuria by urine microalbumin-to-creatinine ratio

    Time frame: 76 Weeks

  14. GFR measurement

    Assessment of renal function through the estimated glomerular filtration rate at 12 months post-transplant

    Time frame: 76 Weeks

  15. Incidence of death

    Time frame: 76 Weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Sep 2031, 56 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Nov 2026 → Jan 2027, primary completion Sep 2029 → Sep 2031 and completion Nov 2029 → Nov 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 2, 2025
StartEst.
Jan 1, 2027was Nov 2026
Primary completionEst.
Sep 1, 2031was Sep 2029
CompletionEst.
Nov 30, 2031was Nov 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 1, 2026→Jan 1, 2027
Nov 6, 2026
Primary completion
Sep 1, 2029→Sep 1, 2031
Nov 6, 2026
Study completion
Nov 30, 2029→Nov 30, 2031
Nov 6, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedFindings that would impact the ability to monitor, diagnose, manage, and follow new onset ocular inflammation.*
Nov 6, 2026
Primary outcomes
2 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameNumber of Adverse Events in each subject12 Months → 76 Weeks
  • Time frameNumber of Serious Adverse Events in each subject12 Months → 76 Weeks
  • DescriptionNumber of Adverse Events in each subject: how it is measured was reworded
  • DescriptionNumber of Serious Adverse Events in each subject: how it is measured was reworded
Nov 6, 2026
Secondary outcomes
11 time frame changed, 4 added, 1 description edited
What changed in the outcomes
  • AddedIncidence of Biopsy Proven Acute RejectionTime frame: 76 Weeks
  • AddedIncidence of treatment for acute rejectionTime frame: 76 Weeks
  • AddedGFR measurementTime frame: 76 Weeks
  • AddedIncidence of deathTime frame: 76 Weeks
  • Time frameIncidence of Biopsy Proven Acute Rejection12 months → 52 Weeks
  • Time frameIncidence of treatment for acute rejection12 Months → 52 Weeks
  • Time frameIncidence of de novo DSA developmentMonths 1, 3, 6, 9, 12 → 52 weeks
  • Time frameIncidence of serious opportunistic infections12 months → 76 Weeks
  • Time frameIncidence of malignancies12 months → 76 Weeks
  • Time frameIncidence of AEs of Special Interest12 months → 76 Weeks
  • Time frameGFR measurement12 months → 52 Weeks
  • Time frameIncidence of death12 months → 52 Weeks
  • Time frameIncidence of graft loss12 months → 52 Weeks
  • Time frameDegree of Proteinuria12 Months → 76 Weeks
  • Time frameDegree of albuminuria12 Months → 76 Weeks
  • DescriptionIncidence of AEs of Special Interest: how it is measured was reworded
Nov 6, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 2 other changes: identifiers and oversight details
  2. Nov 6, 2026
    Start date Nov 1, 2026→Jan 1, 2027
    Primary completion Sep 1, 2029→Sep 1, 2031
    Study completion Nov 30, 2029→Nov 30, 2031
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedFindings that would impact the ability to monitor, diagnose, manage, and follow new onset ocular inflammation.*
    Primary outcomes 2 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameNumber of Adverse Events in each subject12 Months → 76 Weeks
    • Time frameNumber of Serious Adverse Events in each subject12 Months → 76 Weeks
    • DescriptionNumber of Adverse Events in each subject: how it is measured was reworded
    • DescriptionNumber of Serious Adverse Events in each subject: how it is measured was reworded
    Secondary outcomes 11 time frame changed, 4 added, 1 description edited
    What changed in the outcomes
    • AddedIncidence of Biopsy Proven Acute RejectionTime frame: 76 Weeks
    • AddedIncidence of treatment for acute rejectionTime frame: 76 Weeks
    • AddedGFR measurementTime frame: 76 Weeks
    • AddedIncidence of deathTime frame: 76 Weeks
    • Time frameIncidence of Biopsy Proven Acute Rejection12 months → 52 Weeks
    • Time frameIncidence of treatment for acute rejection12 Months → 52 Weeks
    • Time frameIncidence of de novo DSA developmentMonths 1, 3, 6, 9, 12 → 52 weeks
    • Time frameIncidence of serious opportunistic infections12 months → 76 Weeks
    • Time frameIncidence of malignancies12 months → 76 Weeks
    • Time frameIncidence of AEs of Special Interest12 months → 76 Weeks
    • Time frameGFR measurement12 months → 52 Weeks
    • Time frameIncidence of death12 months → 52 Weeks
    • Time frameIncidence of graft loss12 months → 52 Weeks
    • Time frameDegree of Proteinuria12 Months → 76 Weeks
    • Time frameDegree of albuminuria12 Months → 76 Weeks
    • DescriptionIncidence of AEs of Special Interest: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07204080
Lead sponsor
Ayman Al Jurdi, MD
Responsible party
Ayman Al Jurdi, MD (Physician, Massachusetts General Hospital) — Sponsor-investigator
First posted
Oct 2, 2025
Start date
Jan 1, 2027 (estimated)
Primary completion
Sep 1, 2031 (estimated)
Completion
Nov 30, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Ayman Al Jurdi, Principal Investigator, MD
Contact
aaljurdi@mgh.harvard.edu
617-726-2000
Ayman Al Jurdi, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion